Can a pill make CAR T-Cells last longer?

NCT ID NCT05044039

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether the drug duvelisib can help CAR T-cells persist longer in people with non-Hodgkin lymphoma or acute lymphocytic leukemia. About 42 adults who have already received a standard CAR T-cell therapy will take duvelisib pills daily. The main goal is to check safety and see if it reduces side effects like cytokine release syndrome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Duvelisib (a PI3K inhibitor pill)
What this could lead to: If it works, this could help CAR T-cells last longer in the body and reduce serious side effects like cytokine release syndrome.
What could go wrong: This is an early phase 1 trial with only 42 participants, so safety and effectiveness are not yet proven. Duvelisib may cause its own side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia non-Hodgkin lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOCYTIC LEUKEMIA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.